Compare Ascendis Pharma A/S (ASND) vs Plby Group Inc (PLBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Plby Group Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Plby Group Inc trades at $1.16 (market cap $134.09M). The key difference: Ascendis Pharma A/S is far larger — about 132.3× Plby Group Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| ASND | PLBY | |
|---|---|---|
Market Cap | $17.74B | $134.09M |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $2.71 |
52-Week Low | $163.32 | $1.14 |
Enterprise Value | $18.11B | $281.90M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PLBY trades at $1.16 with no recent price movement, showing technical bearish signals despite oversold RSI readings. The company has shown improving fundamentals with revenue stabilizing around $120-122 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent positive developments include Russell index inclusion and a strategic share repurchase program. Operating cash flow turned positive in 2025 after years of negative performance, though the company maintains high debt levels with a debt-to-asset ratio of 59.52%.
While PLBY shows operational improvement and strong analyst support (75% buy ratings), significant risks remain including negative shareholder equity, high debt burden, and inconsistent earnings performance. The stock presents a turnaround opportunity if management can sustain EBITDA growth and debt reduction, but requires careful monitoring of cash flow sustainability and licensing revenue stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
